Chemotherapy for Advanced Breast Cancer – How Long Should it Continue?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Chemotherapy is given to most women with advanced breast cancer, but its optimal duration is poorly defined. A systematic review identified four randomised trials comparing more with fewer cycles of the same chemotherapy in women with advanced breast cancer. Meta-analysis of these four trials including 766 women showed a modest, survival advantage for women randomized to more cycles of chemotherapy (median survival 23% longer with more cycles, p = 0.01). Small increments in survival duration are valued highly by women with breast cancer. Quality of life was also better with more cycles of chemotherapy than fewer in the one trial that measured it. The combined evidence from these trials supports a policy of continuing chemotherapy in the absence of disease progression or significant side effects. Decisions about continuing or stopping treatment should be made by the patient and doctor guided by monitoring and consideration of symptoms, signs, side effects, quality of life and preferences.
- Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: pp. 930-942
- Stockler M, Wilcken N: The management of advanced breast cancer: systematic reviews of randomised controlled trials regarding the use of cytotoxic chemotherapy and endocrine therapy. For the Advanced Breast Cancer Working Party of the NHMRC National Breast Cancer Centre.
- Stockler, M, Wilcken, N, Ghersi, D, Simes, RJ (2000) Systematic reviews of systemic therapy for advanced breast cancer. Cancer Treatment Rev 26: pp. 151-168
- Stockler, M, Wilcken, N, Coates, A (1997) Chemotherapy for metastatic breast cancer-when is enough?. Eur J Cancer 33: pp. 2147-2148
- Coates, A, Gebski, V, Bishop, JF, Jeal, PN, Woods, RL, Snyder, R (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317: pp. 1490-1495
- Coates, A, Byrne, M, Bishop, JF, Forbes, JF (1988) Intermittent versus continuous chemotherapy for breast cancer. N Engl J Med 318: pp. 1468
- Harris, AL, Cantwell, BM, Carmichael, J, Wilson, R, Farndon, J, Dawes, P (1990) Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 335: pp. 186-190
- Ejlertsen, B, Pfeiffer, P, Pedersen, D, Mouridsen, HT, Rose, C, Overgaard, (1993) Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29: pp. 527-531
- Gregory, RK, Powles, TJ, Chang, J, Ashley, S (1997) A randomized trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 33: pp. 2194-2197
- Duric, V, Stockler, M (2001) A systematic review of studies assessing patients' preferences for adjuvant chemotherapy in early breast cancer: What makes it worthwhile?. Lancet Oncol 2: pp. 691-697
- Slevin, ML, Stubbs, L, Plant, HJ (1990) Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300: pp. 1458-1460
- Chemotherapy for Advanced Breast Cancer – How Long Should it Continue?
Breast Cancer Research and Treatment
Volume 81, Issue 1 Supplement, pp 49-52
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- advanced breast cancer
- randomised clinical trials
- Industry Sectors
- Author Affiliations
- 1. Department of Medicine and School of Public Health, University of Sydney, NSW, Australia
- 2. NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
- 3. Department of Medical Oncology, Sydney Cancer Centre, NSW, Australia
- 4. Departments of Medicine and School of Public Health, University of Sydney, NSW, Australia
- 5. Department of Medical Oncology and Palliative Care, Westmead Hospital, NSW, Australia
- 6. The Cancer Council Australia, NSW, Australia